nach oben

NeuroMolecular Medicine

Erschienen in:

01.03.2013 | Review Paper

Deregulated Chromatin Remodeling in the Pathobiology of Brain Tumors

verfasst von: Anastasia Spyropoulou, Christina Piperi, Christos Adamopoulos, Athanasios G. Papavassiliou

Erschienen in: NeuroMolecular Medicine | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Brain tumors encompass a heterogeneous group of malignant tumors with variable histopathology, aggressiveness, clinical outcome and prognosis. Current gene expression profiling studies indicate interplay of genetic and epigenetic alterations in their pathobiology. A central molecular event underlying epigenetics is the alteration of chromatin structure by post-translational modifications of DNA and histones as well as nucleosome repositioning. Dynamic remodeling of the fundamental nucleosomal structure of chromatin or covalent histone marks located in core histones regulate main cellular processes including DNA methylation, replication, DNA-damage repair as well as gene expression. Deregulation of these processes has been linked to tumor suppressor gene silencing, cancer initiation and progression. The reversible nature of deregulated chromatin structure by DNA methylation and histone deacetylation inhibitors, leading to re-expression of tumor suppressor genes, makes chromatin-remodeling pathways as promising therapeutic targets. In fact, a considerable number of these inhibitors are being tested today either alone or in combination with other agents or conventional treatments in the management of brain tumors with considerable success. In this review, we focus on the mechanisms underpinning deregulated chromatin remodeling in brain tumors, discuss their potential clinical implications and highlight the advances toward new therapeutic strategies.

Aguilera, D. G., Das, C. M., Sinnappah-Kang, N. D., Joyce, C., Taylor, P. H., Wen, S., et al. (2009). Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. Journal of Neuro-oncology, 93, 303–318.PubMedCrossRef

Alaminos, M., Davalos, V., Ropero, S., Setien, F., Paz, M. F., Herranz, M., et al. (2005). EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Research, 65, 2565–2571.PubMedCrossRef

Alonso, M. E., Bello, M. J., Gonzalez-Gomez, P., Arjona, D., Lomas, J., de Campos, J. M., et al. (2003). Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genetics and Cytogenetics, 144, 134–142.PubMedCrossRef

Alonso, M. E., Bello, M. J., Gonzalez-Gomez, P., Arjona, D., de Campos, J. M., Gutierrez, M., et al. (2004). Aberrant CpG island methylation of multiple genes in ependymal tumors. Journal of Neuro-oncology, 67, 159–165.PubMedCrossRef

Alonso, M. M., Diez-Valle, R., Manterola, L., Rubio, A., Liu, D., Cortes-Santiago, N., et al. (2011). Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS ONE, 6, e26740.PubMedCrossRef

An, Z., Gluck, C. B., Choy, M. L., & Kaufman, L. J. (2010). Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture. Cancer Letters, 292, 215–227.PubMedCrossRef

Anderton, J. A., Lindsey, J. C., Lusher, M. E., Gilbertson, R. J., Bailey, S., Ellison, D. W., et al. (2008). Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. Neuro-oncology, 10, 981–994.PubMedCrossRef

Arts, J., Angibaud, P., Marien, A., Floren, W., Janssens, B., King, P., et al. (2007). R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. British Journal of Cancer, 97, 1344–1353.PubMedCrossRef

Bangert, A., Hacker, S., Cristofanon, S., Debatin, K. M., & Fulda, S. (2011). Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275. Anti-Cancer Drugs, 22, 494–499.PubMedCrossRef

Bao, Y., & Shen, X. (2007). SnapShot: Chromatin remodeling complexes. Cell, 129, 632.PubMedCrossRef

Becker, P. B., & Horz, W. (2002). ATP-dependent nucleosome remodeling. Annual Review of Biochemistry, 71, 247–273.PubMedCrossRef

Berdasco, M., Ropero, S., Setien, F., Fraga, M. F., Lapunzina, P., Losson, R., et al. (2009). Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proceedings of the National Academy of Sciences of the United States of America, 106, 21830–21835.PubMedCrossRef

Bhat, K. P., Pelloski, C. E., Zhang, Y., Kim, S. H., deLaCruz, C., Rehli, M., et al. (2008). Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2. FEBS Letters, 582, 3193–3200.PubMedCrossRef

Biegel, J. A., Zhou, J. Y., Rorke, L. B., Stenstrom, C., Wainwright, L. M., & Fogelgren, B. (1999). Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Research, 59, 74–79.PubMed

Biegel, J. A., Tan, L., Zhang, F., Wainwright, L., Russo, P., & Rorke, L. B. (2002). Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clinical Cancer Research, 8, 3461–3467.PubMed

Bonisch, C., Nieratschker, S. M., Orfanos, N. K., & Hake, S. B. (2008). Chromatin proteomics and epigenetic regulatory circuits. Expert Review of Proteomics, 5, 105–119.PubMedCrossRef

Boulay, J. L., Ionescu, M. C., Sivasankaran, B., Labuhn, M., Dolder-Schlienger, B., Taylor, E., et al. (2009). The 10q25.3-26.1 G protein-coupled receptor gene GPR26 is epigenetically silenced in human gliomas. International Journal of Oncology, 35, 1123–1131.PubMedCrossRef

Brodeur, G. M., Sekhon, G., & Goldstein, M. N. (1977). Chromosomal aberrations in human neuroblastomas. Cancer, 40, 2256–2263.PubMedCrossRef

Brose, K., Bland, K. S., Wang, K. H., Arnott, D., Henzel, W., Goodman, C. S., et al. (1999). Slit proteins bind Robo receptors and have an evolutionarily conserved role in repulsive axon guidance. Cell, 96, 795–806.PubMedCrossRef

Bruna, A., Darken, R. S., Rojo, F., Ocana, A., Penuelas, S., Arias, A., et al. (2007). High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell, 11, 147–160.PubMedCrossRef

Cadieux, B., Ching, T. T., VandenBerg, S. R., & Costello, J. F. (2006). Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Research, 66, 8469–8476.PubMedCrossRef

Campos, B., Bermejo, J. L., Han, L., Felsberg, J., Ahmadi, R., Grabe, N., et al. (2011). Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Science, 102, 387–392.PubMedCrossRef

Canettieri, G., Di Marcotullio, L., Greco, A., Coni, S., Antonucci, L., Infante, P., et al. (2010). Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nature Cell Biology, 12, 132–142.PubMedCrossRef

Caren, H., Djos, A., Nethander, M., Sjoberg, R. M., Kogner, P., Enstrom, C., et al. (2011). Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer, 11, 66.PubMedCrossRef

Cecener, G., Tunca, B., Egeli, U., Bekar, A., Tezcan, G., Erturk, E., et al. (2012). The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma. Cellular and Molecular Neurobiology, 32, 237–244.PubMedCrossRef

Chernov, A. V., Sounni, N. E., Remacle, A. G., & Strongin, A. Y. (2009). Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. Journal of Biological Chemistry, 284, 12727–12734.PubMedCrossRef

Chernov, A. V., Baranovskaya, S., Golubkov, V. S., Wakeman, D. R., Snyder, E. Y., Williams, R., et al. (2010). Microarray-based transcriptional and epigenetic profiling of matrix metalloproteinases, collagens, and related genes in cancer. The Journal of Biological Chemistry, 285, 19647–19659.PubMedCrossRef

Cho, K. S., Elizondo, L. I., & Boerkoel, C. F. (2004). Advances in chromatin remodeling and human disease. Current Opinion in Genetics & Development, 14, 308–315.CrossRef

Chodavarapu, R. K., Feng, S., Bernatavichute, Y. V., Chen, P. Y., Stroud, H., Yu, Y., et al. (2010). Relationship between nucleosome positioning and DNA methylation. Nature, 466, 388–392.PubMedCrossRef

Cogdell, D., Chung, W., Liu, Y., McDonald, J. M., Aldape, K., Issa, J. P., et al. (2011). Tumor-associated methylation of the putative tumor suppressor AJAP1 gene and association between decreased AJAP1 expression and shorter survival in patients with glioma. Chinese Journal of Cancer, 30, 247–253.PubMedCrossRef

Costa, F. F. (2008). Non-coding RNAs, epigenetics and complexity. Gene, 410, 9–17.PubMedCrossRef

Costa, B. M., Smith, J. S., Chen, Y., Chen, J., Phillips, H. S., Aldape, K. D., et al. (2010). Reversing HOXA9 oncogene activation by PI3 K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Research, 70, 453–462.PubMedCrossRef

Dallol, A., Krex, D., Hesson, L., Eng, C., Maher, E. R., & Latif, F. (2003). Frequent epigenetic inactivation of the SLIT2 gene in gliomas. Oncogene, 22, 4611–4616.PubMedCrossRef

Das, C. M., Aguilera, D., Vasquez, H., Prasad, P., Zhang, M., Wolff, J. E., et al. (2007). Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. Journal of Neuro-oncology, 85, 159–170.PubMedCrossRef

Davis, F. G., McCarthy, B. J., Freels, S., Kupelian, V., & Bondy, M. L. (1999). The conditional probability of survival of patients with primary malignant brain tumors: Surveillance, epidemiology, and end results (SEER) data. Cancer, 85, 485–491.PubMedCrossRef

de Bono, J. S., Kristeleit, R., Tolcher, A., Fong, P., Pacey, S., Karavasilis, V., et al. (2008). Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clinical Cancer Research, 14, 6663–6673.PubMedCrossRef

DeCristofaro, M. F., Betz, B. L., Wang, W., & Weissman, B. E. (1999). Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms’ tumors. Oncogene, 18, 7559–7565.PubMedCrossRef

Diede, S. J., Guenthoer, J., Geng, L. N., Mahoney, S. E., Marotta, M., Olson, J. M., et al. (2010). DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. Proceedings of the National Academy of Sciences of the United States of America, 107, 234–239.PubMedCrossRef

Dou, Y., Milne, T. A., Tackett, A. J., Smith, E. R., Fukuda, A., Wysocka, J., et al. (2005). Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell, 121, 873–885.PubMedCrossRef

Drappatz, J., Lee, E. Q., Hammond, S., Grimm, S. A., Norden, A. D., Beroukhim, R., et al. (2012). Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. Journal of Neuro-oncology, 107, 133–138.PubMedCrossRef

Egler, V., Korur, S., Failly, M., Boulay, J. L., Imber, R., Lino, M. M., et al. (2008). Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. Clinical Cancer Research, 14, 3132–3140.PubMedCrossRef

Ellis, L., Pan, Y., Smyth, G. K., George, D. J., McCormack, C., Williams-Truax, R., et al. (2008). Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clinical Cancer Research, 14, 4500–4510.PubMedCrossRef

Elsheikh, S. E., Green, A. R., Rakha, E. A., Powe, D. G., Ahmed, R. A., Collins, H. M., et al. (2009). Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Research, 69, 3802–3809.PubMedCrossRef

Entin-Meer, M., Yang, X., VandenBerg, S. R., Lamborn, K. R., Nudelman, A., Rephaeli, A., et al. (2007). In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro-oncology, 9, 82–88.PubMedCrossRef

Esteller, M. (2002). CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene, 21, 5427–5440.PubMedCrossRef

Esteller, M. (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Reviews Genetics, 8, 286–298.PubMedCrossRef

Farioli-Vecchioli, S., Tanori, M., Micheli, L., Mancuso, M., Leonardi, L., Saran, A., et al. (2007). Inhibition of medulloblastoma tumorigenesis by the antiproliferative and pro-differentiative gene PC3. FASEB Journal, 21, 2215–2225.PubMedCrossRef

Felsberg, J., Yan, P. S., Huang, T. H., Milde, U., Schramm, J., Wiestler, O. D., et al. (2006). DNA methylation and allelic losses on chromosome arm 14q in oligodendroglial tumours. Neuropathology and Applied Neurobiology, 32, 517–524.PubMedCrossRef

Foltz, G., Ryu, G. Y., Yoon, J. G., Nelson, T., Fahey, J., Frakes, A., et al. (2006). Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Research, 66, 6665–6674.PubMedCrossRef

Fotheringham, S., Epping, M. T., Stimson, L., Khan, O., Wood, V., Pezzella, F., et al. (2009). Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell, 15, 57–66.PubMedCrossRef

Fouladi, M., Park, J. R., Stewart, C. F., Gilbertson, R. J., Schaiquevich, P., Sun, J., et al. (2010). Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children’s Oncology Group phase I consortium report. Journal of Clinical Oncology, 28, 3623–3629.PubMedCrossRef

Friday, B. B., Anderson, S. K., Buckner, J., Yu, C., Giannini, C., Geoffroy, F., et al. (2012). Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro-oncology, 14, 215–221.PubMedCrossRef

Fujisawa, H., Takabatake, Y., Fukusato, T., Tachibana, O., Tsuchiya, Y., & Yamashita, J. (2003). Molecular analysis of the rhabdoid predisposition syndrome in a child: A novel germline hSNF5/INI1 mutation and absence of c-myc amplification. Journal of Neuro-oncology, 63, 257–262.PubMedCrossRef

Fujita, T., Igarashi, J., Okawa, E. R., Gotoh, T., Manne, J., Kolla, V., et al. (2008). CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. Journal of the National Cancer Institute, 100, 940–949.PubMedCrossRef

Furchert, S. E., Lanvers-Kaminsky, C., Juurgens, H., Jung, M., Loidl, A., & Fruhwald, M. C. (2007). Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. International Journal of Cancer, 120, 1787–1794.CrossRef

Galanis, E., Jaeckle, K. A., Maurer, M. J., Reid, J. M., Ames, M. M., Hardwick, J. S., et al. (2009). Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. Journal of Clinical Oncology, 27, 2052–2058.PubMedCrossRef

Gao, J., Chen, T., Liu, J., Liu, W., Hu, G., Guo, X., et al. (2009). Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-Trichostatin A through Sp1 binding site. Glia, 57, 989–999.PubMedCrossRef

Gartel, A. L., & Kandel, E. S. (2008). miRNAs: Little known mediators of oncogenesis. Seminars in Cancer Biology, 18, 103–110.PubMedCrossRef

George, P., Bali, P., Annavarapu, S., Scuto, A., Fiskus, W., Guo, F., et al. (2005). Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood, 105, 1768–1776.PubMedCrossRef

Getun, I. V., Wu, Z. K., Khalil, A. M., & Bois, P. R. (2010). Nucleosome occupancy landscape and dynamics at mouse recombination hotspots. EMBO Reports, 11, 555–560.PubMedCrossRef

Gojo, I., Jiemjit, A., Trepel, J. B., Sparreboom, A., Figg, W. D., Rollins, S., et al. (2007). Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood, 109, 2781–2790.PubMed

Guidi, C. J., Sands, A. T., Zambrowicz, B. P., Turner, T. K., Demers, D. A., Webster, W., et al. (2001). Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Molecular and Cellular Biology, 21, 3598–3603.PubMedCrossRef

Guidi, C. J., Mudhasani, R., Hoover, K., Koff, A., Leav, I., Imbalzano, A. N., et al. (2006). Functional interaction of the retinoblastoma and Ini1/Snf5 tumor suppressors in cell growth and pituitary tumorigenesis. Cancer Research, 66, 8076–8082.PubMedCrossRef

Hamilton, D. W., Lusher, M. E., Lindsey, J. C., Ellison, D. W., & Clifford, S. C. (2005). Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. Cancer Letters, 227, 75–81.PubMedCrossRef

Hayry, V., Tanner, M., Blom, T., Tynninen, O., Roselli, A., Ollikainen, M., et al. (2008). Copy number alterations of the polycomb gene BMI1 in gliomas. Acta Neuropathologica, 116, 97–102.PubMedCrossRef

Hsu, Y. F., Sheu, J. R., Hsiao, G., Lin, C. H., Chang, T. H., Chiu, P. T., et al. (2011). p53 in trichostatin A induced C6 glioma cell death. Biochimica et Biophysica Acta, 1810, 504–513.PubMedCrossRef

Huang, J., Chen, K., Gong, W., Dunlop, N. M., Howard, O. M., Bian, X., et al. (2009). Regulation of the leucocyte chemoattractant receptor FPR in glioblastoma cells by cell differentiation. Carcinogenesis, 30, 348–355.PubMedCrossRef

Huang, W. J., Lin, C. W., Lee, C. Y., Chi, L. L., Chao, Y. C., Wang, H. N., et al. (2011). NBM-HD-3, a novel histone deacetylase inhibitor with anticancer activity through modulation of PTEN and AKT in brain cancer cells. Journal of Ethnopharmacology, 136, 156–167.PubMedCrossRef

Inda, M. M., Munoz, J., Coullin, P., Fauvet, D., Danglot, G., Tunon, T., et al. (2006). High promoter hypermethylation frequency of p14/ARF in supratentorial PNET but not in medulloblastoma. Histopathology, 48, 579–587.PubMedCrossRef

Jackson, E. M., Sievert, A. J., Gai, X., Hakonarson, H., Judkins, A. R., Tooke, L., et al. (2009). Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors. Clinical Cancer Research, 15, 1923–1930.PubMedCrossRef

Jane, E. P., Premkumar, D. R., Addo-Yobo, S. O., & Pollack, I. F. (2009). Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells. The Journal of Pharmacology and Experimental Therapeutics, 331, 327–337.PubMedCrossRef

Johnstone, R. W. (2002). Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Reviews Drug Discovery, 1, 287–299.PubMedCrossRef

Jung, Y., Park, J., Bang, Y. J., & Kim, T. Y. (2008). Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers. Laboratory Investigation, 88, 153–160.PubMedCrossRef

Khan, O., & La Thangue, N. B. (2012). HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications. Immunology and Cell Biology, 90, 85–94.PubMedCrossRef

Kim, T. Y., Zhong, S., Fields, C. R., Kim, J. H., & Robertson, K. D. (2006). Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Research, 66, 7490–7501.PubMedCrossRef

Knobbe, C. B., Reifenberger, J., Blaschke, B., & Reifenberger, G. (2004). Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. Journal of the National Cancer Institute, 96, 483–486.PubMedCrossRef

Konduri, S. D., Srivenugopal, K. S., Yanamandra, N., Dinh, D. H., Olivero, W. C., Gujrati, M., et al. (2003). Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. Oncogene, 22, 4509–4516.PubMedCrossRef

Kongkham, P. N., Northcott, P. A., Ra, Y. S., Nakahara, Y., Mainprize, T. G., Croul, S. E., et al. (2008). An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. Cancer Research, 68, 9945–9953.PubMedCrossRef

Kongkham, P. N., Northcott, P. A., Croul, S. E., Smith, C. A., Taylor, M. D., & Rutka, J. T. (2010). The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma. Oncogene, 29, 3017–3024.PubMedCrossRef

Kumar, K. S., Sonnemann, J., & Beck, J. F. (2006). Histone deacetylase inhibitors induce cell death in supratentorial primitive neuroectodermal tumor cells. Oncology Reports, 16, 1047–1052.PubMed

Lehnertz, B., Ueda, Y., Derijck, A. A., Braunschweig, U., Perez-Burgos, L., Kubicek, S., et al. (2003). Suv39 h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Current Biology, 13, 1192–1200.PubMedCrossRef

Lindsey, J. C., Anderton, J. A., Lusher, M. E., & Clifford, S. C. (2005). Epigenetic events in medulloblastoma development. Neurosurgical Focus, 19, E10.PubMedCrossRef

Lindsey, J. C., Lusher, M. E., Strathdee, G., Brown, R., Gilbertson, R. J., Bailey, S., et al. (2006). Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. International Journal of Cancer, 118, 346–352.CrossRef

Liu, B. L., Cheng, J. X., Zhang, X., Wang, R., Zhang, W., Lin, H., et al. (2010). Global histone modification patterns as prognostic markers to classify glioma patients. Cancer Epidemiology, Biomarkers and Prevention, 19, 2888–2896.PubMedCrossRef

Lo, W. S., Duggan, L., Emre, N. C., Belotserkovskya, R., Lane, W. S., Shiekhattar, R., et al. (2001). Snf1–a histone kinase that works in concert with the histone acetyltransferase Gcn5 to regulate transcription. Science, 293, 1142–1146.PubMedCrossRef

Loeffler, J. S., Alexander, E., 3rd, Shea, W. M., Wen, P. Y., Fine, H. A., Kooy, H. M., et al. (1992). Radiosurgery as part of the initial management of patients with malignant gliomas. Journal of Clinical Oncology, 10, 1379–1385.PubMed

Lopez, C. A., Feng, F. Y., Herman, J. M., Nyati, M. K., Lawrence, T. S., & Ljungman, M. (2007). Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation. International Journal of Radiation Oncology Biology Physics, 69, 214–220.CrossRef

Lucio-Eterovic, A. K., Cortez, M. A., Valera, E. T., Motta, F. J., Queiroz, R. G., Machado, H. R., et al. (2008). Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer, 8, 243.PubMedCrossRef

Maegawa, S., Yoshioka, H., Itaba, N., Kubota, N., Nishihara, S., Shirayoshi, Y., et al. (2001). Epigenetic silencing of PEG3 gene expression in human glioma cell lines. Molecular Carcinogenesis, 31, 1–9.PubMedCrossRef

Marino, A. M., Sofiadis, A., Baryawno, N., Johnsen, J. I., Larsson, C., Vukojevic, V., et al. (2011). Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models. Biochemical and Biophysical Research Communications, 411, 208–212.PubMedCrossRef

Martinez, R., & Esteller, M. (2010). The DNA methylome of glioblastoma multiforme. Neurobiology of Disease, 39, 40–46.PubMedCrossRef

Masoudi, A., Elopre, M., Amini, E., Nagel, M. E., Ater, J. L., Gopalakrishnan, V., et al. (2008). Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Research, 28, 2437–2442.PubMed

McDonald, J. M., Dunlap, S., Cogdell, D., Dunmire, V., Wei, Q., Starzinski-Powitz, A., et al. (2006). The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration. Cancer Biology & Therapy, 5, 300–304.CrossRef

Mehnert, J. M., & Kelly, W. K. (2007). Histone deacetylase inhibitors: biology and mechanism of action. The Cancer Journal, 13, 23–29.PubMedCrossRef

Meissner, A., Mikkelsen, T. S., Gu, H., Wernig, M., Hanna, J., Sivachenko, A., et al. (2008). Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature, 454, 766–770.PubMed

Michalowski, M. B., de Fraipont, F., Michelland, S., Entz-Werle, N., Grill, J., Pasquier, B., et al. (2006). Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genetics and Cytogenetics, 166, 74–81.PubMedCrossRef

Milde, T., Oehme, I., Korshunov, A., Kopp-Schneider, A., Remke, M., Northcott, P., et al. (2010). HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clinical Cancer Research, 16, 3240–3252.PubMedCrossRef

Minucci, S., & Pelicci, P. G. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews Cancer, 6, 38–51.PubMedCrossRef

Miyanaga, A., Gemma, A., Noro, R., Kataoka, K., Matsuda, K., Nara, M., et al. (2008). Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Molecular Cancer Therapeutics, 7, 1923–1930.PubMedCrossRef

Mottet, D., Pirotte, S., Lamour, V., Hagedorn, M., Javerzat, S., Bikfalvi, A., et al. (2009). HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene, 28, 243–256.PubMedCrossRef

Muchardt, C., Sardet, C., Bourachot, B., Onufryk, C., & Yaniv, M. (1995). A human protein with homology to Saccharomyces cerevisiae SNF5 interacts with the potential helicase hbrm. Nucleic Acids Research, 23, 1127–1132.PubMedCrossRef

Muhlisch, J., Schwering, A., Grotzer, M., Vince, G. H., Roggendorf, W., Hagemann, C., et al. (2006). Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood. Oncogene, 25, 1111–1117.PubMedCrossRef

Murr, R. (2010). Interplay between different epigenetic modifications and mechanisms. Advances in Genetics, 70, 101–141.PubMedCrossRef

Nagarajan, R. P., & Costello, J. F. (2009). Molecular epigenetics and genetics in neuro-oncology. Neurotherapeutics, 6, 436–446.PubMedCrossRef

Nakahara, Y., Northcott, P. A., Li, M., Kongkham, P. N., Smith, C., Yan, H., et al. (2010). Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma. Neoplasia, 12, 20–27.PubMed

Nakayama, J., Rice, J. C., Strahl, B. D., Allis, C. D., & Grewal, S. I. (2001). Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science, 292, 110–113.PubMedCrossRef

Nikaki, A., Piperi, C., & Papavassiliou, A. G. (2012). Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy. Expert Opinion on Investigational Drugs, 21, 1475–1488.

Northcott, P. A., Nakahara, Y., Wu, X., Feuk, L., Ellison, D. W., Croul, S., et al. (2009). Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nature Genetics, 41, 465–472.PubMedCrossRef

Oppel, F., Muller, N., Schackert, G., Hendruschk, S., Martin, D., Geiger, K. D., et al. (2011). SOX2-RNAi attenuates S-phase entry and induces RhoA-dependent switch to protease-independent amoeboid migration in human glioma cells. Molecular Cancer, 10, 137.PubMedCrossRef

Palavalli, L. H., Prickett, T. D., Wunderlich, J. R., Wei, X., Burrell, A. S., Porter-Gill, P., et al. (2009). Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nature Genetics, 41, 518–520.PubMedCrossRef

Pang, J. C., Chang, Q., Chung, Y. F., Teo, J. G., Poon, W. S., Zhou, L. F., et al. (2005). Epigenetic inactivation of DLC-1 in supratentorial primitive neuroectodermal tumor. Human Pathology, 36, 36–43.PubMedCrossRef

Pang, J. C., Li, K. K., Lau, K. M., Ng, Y. L., Wong, J., Chung, N. Y., et al. (2010). KIAA0495/PDAM is frequently downregulated in oligodendroglial tumors and its knockdown by siRNA induces cisplatin resistance in glioma cells. Brain Pathology, 20, 1021–1032.PubMedCrossRef

Papi, A., Ferreri, A. M., Rocchi, P., Guerra, F., & Orlandi, M. (2010). Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells. Anticancer Research, 30, 535–540.PubMed

Parsons, D. W., Jones, S., Zhang, X., Lin, J. C., Leary, R. J., Angenendt, P., et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 1807–1812.PubMedCrossRef

Parsons, D. W., Li, M., Zhang, X., Jones, S., Leary, R. J., Lin, J. C., et al. (2011). The genetic landscape of the childhood cancer medulloblastoma. Science, 331, 435–439.PubMedCrossRef

Peyre, M., Commo, F., Dantas-Barbosa, C., Andreiuolo, F., Puget, S., Lacroix, L., et al. (2010). Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis. PLoS ONE, 5, e12932.PubMedCrossRef

Pfister, S., Schlaeger, C., Mendrzyk, F., Wittmann, A., Benner, A., Kulozik, A., et al. (2007). Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma. Nucleic Acids Research, 35, e51.PubMedCrossRef

Pfister, S. M., Korshunov, A., Kool, M., Hasselblatt, M., Eberhart, C., & Taylor, M. D. (2010). Molecular diagnostics of CNS embryonal tumors. Acta Neuropathologica, 120, 553–566.PubMedCrossRef

Piperi, C., Themistocleous, M. S., Papavassiliou, G. A., Farmaki, E., Levidou, G., Korkolopoulou, P., et al. (2010). High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome. Molecular Medicine, 16, 1–9.PubMedCrossRef

Portela, A., & Esteller, M. (2010). Epigenetic modifications and human disease. Nature Biotechnology, 28, 1057–1068.PubMedCrossRef

Potts, C. B., Albitar, X. M., Anderson, C. K., Baritaki, S., Berkers, C., Bonavida, B., et al. (2011a). Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Current Cancer Drug Targets, 11, 254–284.CrossRef

Potts, R. C., Zhang, P., Wurster, A. L., Precht, P., Mughal, M. R., Wood, W. H., 3rd, et al. (2011b). CHD5, a brain-specific paralog of Mi2 chromatin remodeling enzymes, regulates expression of neuronal genes. PLoS ONE, 6, e24515.PubMedCrossRef

Premkumar, D. R., Jane, E. P., Agostino, N. R., Didomenico, J. D., & Pollack, I. F. (2011). Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Molecular Carcinogenesis,. doi:10.1002/mc.21835.

Ramalingam, S. S., Kummar, S., Sarantopoulos, J., Shibata, S., LoRusso, P., Yerk, M., et al. (2010). Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Journal of Clinical Oncology, 28, 4507–4512.PubMedCrossRef

Rea, S., Eisenhaber, F., O’Carroll, D., Strahl, B. D., Sun, Z. W., Schmid, M., et al. (2000). Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature, 406, 593–599.PubMedCrossRef

Restrepo, A., Smith, C. A., Agnihotri, S., Shekarforoush, M., Kongkham, P. N., Seol, H. J., et al. (2011). Epigenetic regulation of glial fibrillary acidic protein by DNA methylation in human malignant gliomas. Neuro-oncology, 13, 42–50.PubMedCrossRef

Roberts, C. W., Galusha, S. A., McMenamin, M. E., Fletcher, C. D., & Orkin, S. H. (2000). Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proceedings of the National Academy of Sciences of the United States of America, 97, 13796–13800.PubMedCrossRef

Rottach, A., Frauer, C., Pichler, G., Bonapace, I. M., Spada, F., & Leonhardt, H. (2010). The multi-domain protein Np95 connects DNA methylation and histone modification. Nucleic Acids Research, 38, 1796–1804.PubMedCrossRef

Rousseau, E., Ruchoux, M. M., Scaravilli, F., Chapon, F., Vinchon, M., De Smet, C., et al. (2003). CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathology and Applied Neurobiology, 29, 574–583.PubMedCrossRef

Rutka, J. T., Hubbard, S. L., Fukuyama, K., Matsuzawa, K., Dirks, P. B., & Becker, L. E. (1994). Effects of antisense glial fibrillary acidic protein complementary DNA on the growth, invasion, and adhesion of human astrocytoma cells. Cancer Research, 54, 3267–3272.PubMed

Ryan, Q. C., Headlee, D., Acharya, M., Sparreboom, A., Trepel, J. B., Ye, J., et al. (2005). Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. Journal of Clinical Oncology, 23, 3912–3922.PubMedCrossRef

Sarcar, B., Kahali, S., & Chinnaiyan, P. (2010). Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines. Journal of Neuro-oncology, 99, 201–207.PubMedCrossRef

Sawa, H., Murakami, H., Kumagai, M., Nakasato, M., Yamauchi, S., Matsuyama, N., et al. (2004). Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathologica, 107, 523–531.PubMedCrossRef

Schmidt, N., Windmann, S., Reifenberger, G., & Riemenschneider, M. J. (2012). DNA hypermethylation and histone modifications downregulate the candidate tumor suppressor gene RRP22 on 22q12 in human gliomas. Brain Pathology, 22, 17–25.PubMedCrossRef

Schmitz, M., Temme, A., Senner, V., Ebner, R., Schwind, S., Stevanovic, S., et al. (2007). Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. British Journal of Cancer, 96, 1293–1301.PubMedCrossRef

Schneppenheim, R., Fruhwald, M. C., Gesk, S., Hasselblatt, M., Jeibmann, A., Kordes, U., et al. (2010). Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. American Journal of Human Genetics, 86, 279–284.PubMedCrossRef

Schuster, J. M., Longo, M., & Nelson, P. S. (2003). Differential expression of bikunin (HAI-2/PB), a proposed mediator of glioma invasion, by demethylation treatment. Journal of Neuro-oncology, 64, 219–225.PubMedCrossRef

Schwartzentruber, J., Korshunov, A., Liu, X. Y., Jones, D. T., Pfaff, E., Jacob, K., et al. (2012). Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 482, 226–231.PubMedCrossRef

Seligson, D. B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M., et al. (2005). Global histone modification patterns predict risk of prostate cancer recurrence. Nature, 435, 1262–1266.PubMedCrossRef

Seligson, D. B., Horvath, S., McBrian, M. A., Mah, V., Yu, H., Tze, S., et al. (2009). Global levels of histone modifications predict prognosis in different cancers. The American Journal of Pathology, 174, 1619–1628.PubMedCrossRef

Sevenet, N., Lellouch-Tubiana, A., Schofield, D., Hoang-Xuan, K., Gessler, M., Birnbaum, D., et al. (1999a). Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Human Molecular Genetics, 8, 2359–2368.PubMedCrossRef

Sevenet, N., Sheridan, E., Amram, D., Schneider, P., Handgretinger, R., & Delattre, O. (1999b). Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. American Journal of Human Genetics, 65, 1342–1348.PubMedCrossRef

Simpson, D. J., Clayton, R. N., & Farrell, W. E. (2002). Preferential loss of Death Associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion. Oncogene, 21, 1217–1224.PubMedCrossRef

Singh, M. M., Manton, C. A., Bhat, K. P., Tsai, W. W., Aldape, K., Barton, M. C., et al. (2011). Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro-oncology, 13, 894–903.PubMedCrossRef

Smits, M., Nilsson, J., Mir, S. E., van der Stoop, P. M., Hulleman, E., Niers, J. M., et al. (2010). miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget, 1, 710–720.PubMed

Spiller, S. E., Ditzler, S. H., Pullar, B. J., & Olson, J. M. (2008). Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). Journal of Neuro-oncology, 87, 133–141.PubMedCrossRef

Steele, N. L., Plumb, J. A., Vidal, L., Tjornelund, J., Knoblauch, P., Rasmussen, A., et al. (2008). A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clinical Cancer Research, 14, 804–810.PubMedCrossRef

Tarasenko, N., Kessler-Icekson, G., Boer, P., Inbal, A., Schlesinger, H., Phillips, D. R., et al. (2012). The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity. Investigational New Drugs, 30, 130–143.PubMedCrossRef

Teider, N., Scott, D. K., Neiss, A., Weeraratne, S. D., Amani, V. M., Wang, Y., et al. (2010). Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma. Neuro-oncology, 12, 1244–1256.PubMed

Tepel, M., Roerig, P., Wolter, M., Gutmann, D. H., Perry, A., Reifenberger, G., et al. (2008). Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. International Journal of Cancer, 123, 2080–2086.CrossRef

Tsai, H. C., Wei, K. C., Tsai, C. N., Huang, Y. C., Chen, P. Y., Chen, S. M., et al. (2012). Effect of valproic acid on the outcome of glioblastoma multiforme. British Journal of Neurosurgery, 26, 347–354.PubMedCrossRef

Tzao, C., Tung, H. J., Jin, J. S., Sun, G. H., Hsu, H. S., Chen, B. H., et al. (2009). Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Modern Pathology, 22, 252–260.PubMedCrossRef

Ugur, H. C., Ramakrishna, N., Bello, L., Menon, L. G., Kim, S. K., Black, P. M., et al. (2007). Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. Journal of Neuro-oncology, 83, 267–275.PubMedCrossRef

Uhlmann, K., Rohde, K., Zeller, C., Szymas, J., Vogel, S., Marczinek, K., et al. (2003). Distinct methylation profiles of glioma subtypes. International Journal of Cancer, 106, 52–59.CrossRef

Unoki, M., Nishidate, T., & Nakamura, Y. (2004). ICBP90, an E2F–1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene, 23, 7601–7610.PubMedCrossRef

Versteege, I., Sevenet, N., Lange, J., Rousseau-Merck, M. F., Ambros, P., Handgretinger, R., et al. (1998). Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature, 394, 203–206.PubMedCrossRef

Vibhakar, R., Foltz, G., Yoon, J. G., Field, L., Lee, H., Ryu, G. Y., et al. (2007). Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma. Neuro-oncology, 9, 135–144.PubMedCrossRef

Vladimirova, V., Mikeska, T., Waha, A., Soerensen, N., Xu, J., Reynolds, P. C., et al. (2009). Aberrant methylation and reduced expression of LHX9 in malignant gliomas of childhood. Neoplasia, 11, 700–711.PubMed

Wagner, J. M., Hackanson, B., Lubbert, M., & Jung, M. (2010). Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clinical Epigenetics, 1, 117–136.PubMedCrossRef

Waha, A., Koch, A., Hartmann, W., Mack, H., Schramm, J., Sorensen, N., et al. (2004). Analysis of HIC-1 methylation and transcription in human ependymomas. International Journal of Cancer, 110, 542–549.CrossRef

Waha, A., Guntner, S., Huang, T. H., Yan, P. S., Arslan, B., Pietsch, T., et al. (2005). Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia, 7, 193–199.PubMedCrossRef

Wang, W., Xue, Y., Zhou, S., Kuo, A., Cairns, B. R., & Crabtree, G. R. (1996). Diversity and specialization of mammalian SWI/SNF complexes. Genes & Development, 10, 2117–2130.CrossRef

Wang, G. G., Allis, C. D., & Chi, P. (2007). Chromatin remodeling and cancer, part II: ATP-dependent chromatin remodeling. Trends in Molecular Medicine, 13, 373–380.PubMedCrossRef

Watanabe, H., Soejima, K., Yasuda, H., Kawada, I., Nakachi, I., Yoda, S., et al. (2008). Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell International, 8, 15.PubMedCrossRef

Wegener, D., Deubzer, H. E., Oehme, I., Milde, T., Hildmann, C., Schwienhorst, A., et al. (2008). HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells. Anti-Cancer Drugs, 19, 849–857.PubMedCrossRef

Wei, L., Hong, S., Yoon, Y., Hwang, S. N., Park, J. C., Zhang, Z., et al. (2012). Early prediction of response to Vorinostat in an orthotopic rat glioma model. NMR in Biomedicine, 25, 1104–1111.PubMedCrossRef

Weller, M., Gorlia, T., Cairncross, J. G., van den Bent, M. J., Mason, W., Belanger, K., et al. (2011). Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology, 77, 1156–1164.PubMedCrossRef

Wiedemann, S. M., Mildner, S. N., Bönisch, C., Israel, L., Maiser, A., Matheisl, S., et al. (2010). Identification and characterization of two novel primate-specific histone H3 variants, H3.X and H3.Y. The Journal of Cell Biology, 190, 777–791.PubMedCrossRef

Wolff, J. E., Kramm, C., Kortmann, R. D., Pietsch, T., Rutkowski, S., Jorch, N., et al. (2008). Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. Journal of Neuro-oncology, 90, 309–314.PubMedCrossRef

National Library of Medicine, U.S. National Institutes of Health (NIH), Food and Drug Administration (FDA). (2012). Available at: http://clinicaltrials.gov/.

Yi, J. M., Tsai, H. C., Glockner, S. C., Lin, S., Ohm, J. E., Easwaran, H., et al. (2008). Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Research, 68, 8094–8103.PubMedCrossRef

Yin, D., Ong, J. M., Hu, J., Desmond, J. C., Kawamata, N., Konda, B. M., et al. (2007). Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clinical Cancer Research, 13, 1045–1052.PubMedCrossRef

Yu, C., Friday, B. B., Yang, L., Atadja, P., Wigle, D., Sarkaria, J., et al. (2008). Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. Neuro-oncology, 10, 309–319.PubMedCrossRef

Titel: Deregulated Chromatin Remodeling in the Pathobiology of Brain Tumors
verfasst von: Anastasia Spyropoulou
Christina Piperi
Christos Adamopoulos
Athanasios G. Papavassiliou
Publikationsdatum: 01.03.2013
Verlag: Humana Press Inc
Erschienen in: NeuroMolecular Medicine / Ausgabe 1/2013
Print ISSN: 1535-1084
Elektronische ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-012-8205-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Variable Phenotypes of Knockin Mice Carrying the M712T Gne Mutation

Decreased Levels of Circulating Adiponectin in Mild Cognitive Impairment and Alzheimer’s Disease

Novel Mutations in Cyclin-Dependent Kinase-Like 5 (CDKL5) Gene in Indian Cases of Rett Syndrome

The Identification of Neuropeptide Y Receptor Subtype Involved in Phenylpropanolamine-induced Increase in Oxidative Stress and Appetite Suppression

Activation of Tetrodotoxin-Resistant Sodium Channel NaV1.9 in Rat Primary Sensory Neurons Contributes to Melittin-Induced Pain Behavior